Catalyst Dossier · compiled by CeliA 🧫

Recordati S.p.A. (REC.MI)

Pharmaceutical Preparations · market cap $11.3B · as of 2026-06-29

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Recordati S.p.A. (REC.MI) is an Italian pharmaceutical company with approximately 4,700 employees and a market cap of roughly $11.3 billion. The company operates a diversified pipeline spanning rare diseases, urology, oncology supportive care, and endocrinology, with lead commercial and late-stage assets including Silodosin (Phase 3, BPH) and Mercaptamine (Phase 3, Cystinosis). No upcoming catalysts are currently calendared, and key financial details including cash, net debt, and annual revenues were not provided in the fact set.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Silodosin	Phase 3	Benign Prostatic Hyperplasia
Methadone	Phase 3	Pain Related to Cancer
Udonitrectag	Phase 2	Neurotrophic Keratitis
osilodrostat	Phase 2	Cushing's Syndrome
Lercanidipine	Phase 2	Essential Hypertension
Rec 0/0438 1 mg or Rec 0/0438 2 mg	Phase 2	Neurogenic Detrusor Overactivity
Mercaptamine	Phase 3	Cystinosis
Pasireotide Diaspartate	Phase 2	Post-Bariatric Hypoglycemia
LCI699	Phase 2	Cushing Syndrome

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for REC.MI (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.